Overview

A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study

Status:
Completed

Trial end date:
2014-01-01

Target enrollment:

Participant gender:

Summary

This was a multicenter, open-label extension study. Patients who received vismodegib (GDC-0449) in a Genentech-sponsored study and who had completed the parent study or who continued to receive vismodegib at the time the parent study closed were eligible for continued treatment in this protocol.

Phase:

Phase 2

Details

Lead Sponsor:

Genentech, Inc.

Treatments:

Bevacizumab